What are the first‑line antiepileptic drugs for children with rolandic (centrotemporal) epilepsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

First-Line Antiepileptic Drugs for Rolandic Epilepsy in Children

Levetiracetam or sulthiame should be used as first-line therapy for children with rolandic epilepsy, with levetiracetam preferred when cognitive preservation is a priority and sulthiame when EEG normalization is the primary goal.

Primary Treatment Recommendations

Levetiracetam as First-Line Agent

  • Levetiracetam demonstrates superior efficacy in reducing rolandic discharges compared to traditional agents, achieving EEG response in 71.4% of patients versus 56.2% with valproate and only 11.2% with carbamazepine 1.
  • The time to achieve EEG response is significantly faster with levetiracetam (14.7 months) compared to valproate (23.1 months) or carbamazepine (36.3 months) 2.
  • Levetiracetam monotherapy correlates with normal cognitive outcomes and helps prevent cognitive decline, making it particularly valuable given that rolandic epilepsy is now recognized as a regional epileptic encephalopathy with broader cognitive implications 3, 4.
  • When compared directly to carbamazepine, levetiracetam significantly improves cognitive performance while maintaining equivalent seizure control 5.

Sulthiame as Alternative First-Line Agent

  • Sulthiame shows significantly higher seizure-freedom rates compared to carbamazepine, oxcarbazepine, or topiramate 1.
  • Sulthiame demonstrates superior EEG normalization, with 4.61 times higher probability of EEG normalization compared to placebo 6.
  • Sulthiame has better tolerability than levetiracetam, with lower rates of treatment withdrawal due to adverse events (RR = 0.20 for sulthiame versus levetiracetam) 6.

Agents to Avoid or Use with Caution

Carbamazepine - Not Recommended

  • Carbamazepine shows poor efficacy in suppressing rolandic discharges, with only 11.2% of patients achieving EEG response 1.
  • Takes significantly longer to achieve any EEG improvement (36.3 months) compared to newer agents 2.
  • Associated with cognitive decline in rolandic epilepsy patients 5.

Valproate - Use with Extreme Caution

  • Polytherapy involving sodium valproate, particularly when combined with other drugs, correlates with cognitive deterioration 3.
  • Sodium valproate plus other drug(s) and levetiracetam plus sodium valproate combinations are specifically linked to poor cognitive outcomes 3.
  • While valproate combined with levetiracetam shows good improvement in spike wave index, the cognitive risks outweigh benefits 3.

Treatment Algorithm

When to Treat

  • Treatment should be considered if it reduces seizures, prevents evolution to atypical forms, or diminishes negative cognitive consequences 7.
  • Given that rolandic epilepsy involves regional spindle disruption extending beyond the epileptic cortex with broad cognitive implications, treatment may be more justified than previously assumed 4.

Specific Dosing Approach

  • Start with levetiracetam monotherapy when cognitive preservation is paramount, particularly in children with academic concerns 3, 5.
  • Consider sulthiame as first-line when EEG normalization is the primary goal or when tolerability concerns exist 6.
  • Avoid polytherapy whenever possible, as it correlates with cognitive deterioration 3.

Important Caveats

Cognitive Monitoring

  • Physicians must screen for subtle cognitive dysfunction affecting academic performance, as rolandic epilepsy represents a regional epileptic encephalopathy with deficits extending to prefrontal, insular, superior temporal, and posterior parietal regions 4.
  • Regional spindle rate deficits predict global cognitive performance, fine motor dexterity, attention, and intelligence 4.

EEG Considerations

  • Initial spike wave index ≥85% and multifocal spikes predict poor cognitive outcomes regardless of treatment 3.
  • Focal spikes correlate with poor improvement in spike wave index 3.

Treatment Duration

  • The disease spontaneously resolves by adolescence, so long-term treatment is not required 4.
  • Monitor for resolution with consideration of medication withdrawal after sustained seizure freedom 4.

References

7
Research

[Treatment of rolandic epilepsy].

Ugeskrift for laeger, 2017

Related Questions

What is the best drug of choice for Rolandic (Benign Childhood Epilepsy with Centrotemporal Spikes) epilepsy?
Does a child with Rolandic epilepsy (benign childhood epilepsy with centro‑temporal spikes) and infrequent brief nocturnal seizures require antiseizure medication?
Should a child with atypical Rolandic epilepsy be treated, and how does its prognosis differ from typical Rolandic epilepsy?
What is the next appropriate action for an 8-year-old boy with benign childhood epilepsy with centro-temporal spikes, persistent seizures, and abnormal EEG findings despite Carbamazepine treatment?
What is the best course of action for an 8-year-old child, weighing 16-17 kg, with a diagnosis of benign occipital lobe epilepsy, who is experiencing break-through seizures despite being on levetiracetam (~29 mg/kg/day) and oxcarbazepine (150 mg twice daily, ~18 mg/kg/day)?
Should amoxicillin/clavulanate (Augmentin) 625 mg be administered three times daily or twice daily in an adult with normal renal function?
How should a newborn with jaundice and a random blood glucose of 54 mg/dL be managed?
Can ventricular hypertrophy cause heart failure?
Should midazolam be administered to an intoxicated, agitated trauma patient with alcohol breath after a motor vehicle collision and lacerations?
How should I manage a newborn with hyperbilirubinemia requiring intensive phototherapy and a borderline low random glucose (~54 mg/dL)?
Are beta‑blockers safe or appropriate for patients with pulmonary hypertension, and when can they be used?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question